The anti CD47 drugs market comprises CD47 targeting therapies that deliver promising outcomes in oncology. CD47 is a cell surface receptor that acts as a "don't eat me" signal to macrophages and other immune cells. Various cancer cells overexpress CD47 to evade phagocytosis by macrophages.
By blocking CD47, these therapies help macrophages identify and clear cancer cells. Some key players are developing antibodies or other inhibitory agents against Anti CD47 Drugs Market to treat both hematological and solid tumors.
The anti CD47 drugs market is estimated to be valued at USD 0.14 Bn in 2024 and is expected to reach USD 1.7 Bn by 2031, growing at a compound annual growth rate (CAGR) of 42.9% from 2024 to 2031.
Key Takeaways
Key players operating in the anti CD47 drugs market are Sino Biological, Forty Seven Inc, Avitro Inc and Celgene Corporation.
Growing incidence of cancer worldwide is a major factor fueling demand for anti CD47 drugs. According to WHO, cancer burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040.
Technological advancements like development of humanized antibody drugs and bispecific antibodies are expanding application scope of anti CD47 therapies. Combination therapies of CD47 inhibitors with immune checkpoint inhibitors are showing promise.
Market Trends
First, combination therapies of CD47 inhibitors with immune checkpoint inhibitors like anti-PD1 drugs are gaining traction. By targeting two immune pathways, these combinations provide synergistic anti-tumor response.
Second, several biotechs are developing next-gen CD47 inhibitors like bispecific antibodies, fusion proteins and non-antibody formats like peptides to address limitations of first-gen antibodies. These new modalities aim for improved efficacy and safety.
Market Opportunities
One major opportunity lies in expanding approvals and use of anti CD47 drugs for treating both hematological and solid tumor indications.
Another opportunity for market expansion stems from ongoing clinical trials evaluating efficacy of different anti CD47 drug combinations for various cancers. Positive outcomes may lead to new combination therapy approvals.
Impact of COVID-19 on Anti CD47 Drugs Market growth:
The outbreak of COVID-19 pandemic has greatly impacted the growth of anti CD47 drugs market. During the pandemic, clinical trials involving anti CD47 drugs were paused to avoid exposure. Various companies announced delays in drug development programs. However, anti CD47 drugs are seen as potential treatment options against COVID-19. Studies show CD47 acts as a shield to viruses and blocking it can help fight infections. This has accelerated R&D efforts of companies.
Pre-pandemic, the market was growing steadily with ongoing clinical trials. Post pandemic, there is renewed focus to streamline development and launch anti CD47 drugs to treat COVID-19. Companies plan to expedite trials, engage with regulatory authorities and enhance manufacturing capacities. Governments are supportive to approve anti-CD47 therapies on priority for COVID-19. The pandemic has highlighted the need for new treatment options. This will boost investments in research and aid faster market growth compared to pre-COVID estimates in the coming years.
Geographical regions:
North America accounts for the largest share of global anti CD47 drugs market in terms of value. This is attributed to presence of major pharmaceutical companies conducting clinical trials of anti CD47 drugs. The US contributes majority of the region's market share due to high healthcare spending and availability of advanced healthcare infrastructure for clinical research.
Asia Pacific region is poised to grow at the fastest rate globally during the forecast period. This is due to increasing investments by international players to tap into large patient pools and support from governments to build local manufacturing facilities. Moreover, growing healthcare expenditure, rising incidence of cancer and improving regulatory framework will further aid market growth in Asia Pacific region over the coming years.
Get more insights on: Anti CD47 Drugs Market
Get this Report in Japanese Language: 抗CD47薬市場
Get this Report in Korean Language: 항 CD47 약물 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)